Search results
Results from the WOW.Com Content Network
On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...
With strong sales of its blockbuster immune-based cancer drug, Keytruda, along with vaccine products, Merck reported revenue rose 9% YoY to $15.78 billion, surpassing LSEG’s estimate of $15.20 ...
A trial of the drug in patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma was stopped for "futility", meaning it was likely to fail, the company said.
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an earlier stage of cancer to demonstrate an OS benefit, in addition to KEYNOTE-A18 in cervical cancer, KEYNOTE-671 in non-small cell ...
(Reuters) -Merck said on Friday its blockbuster immunotherapy Keytruda, in combination with chemoradiotherapy, met the main goal of improving overall survival for newly diagnosed patients with a ...
The cancer center was also named one of Working Mother Magazine's 100 Best Companies for 10th time. [53] In 2023, Moffitt was ranked No. 10 in the nation and the top-ranked cancer hospital in Florida and the Southeast in Newsweek’s 2023 list of “America’s Best Cancer Hospitals.” [54]
The therapy addresses the patients who are diagnosed with a sub-type of breast cancer, which has an increased risk of spread to lymph nodes and recurrence. Merck's Keytruda meets main goal in late ...